Johnson & Johnson (JNJ) has finalized a deal to buy Swiss biotech Actelion (ALIOF) . The $30 billion takeover will see Johnson & Johnson spin out Actelion's R&D unit into a separate business.
Unilever (UN) has posted weaker-than-expected full-year earnings. The company's decline, mixed with a stronger pound, held down the FTSE 100.
Royal Bank of Scotland (RBS) has set aside $3.8 billion in Department of Justice provisions, in anticipation of an upcoming settlement. RBS says provisions will not impact distributable reserves.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.
Email
Email sent
Thank you, your email to has been sent successfully.
